These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 34246621)

  • 1. Pityriasis Rubra Pilaris Response to IL-17A Inhibition Is Associated with IL-17C and CCL20 Protein Levels.
    Strunck JL; Cutler B; Rajpal B; Kent G; Haynes D; Topham CA; Ortega-Loayza AG; Yang D; Wang Z; Liu Y; Cassidy P; Greiling TM
    J Invest Dermatol; 2022 Jan; 142(1):235-239.e1. PubMed ID: 34246621
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment of pityriasis rubra pilaris with guselkumab: Serum CCL20 as a potential marker for the disease activity.
    Nagai H; Jimbo H; Matsuura S; Tatsuoka S; Shiraki E; Nishigori C
    Dermatol Ther; 2020 Nov; 33(6):e14403. PubMed ID: 33044038
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of Ixekizumab Treatment for Patients With Pityriasis Rubra Pilaris: A Single-Arm Trial.
    Haynes D; Strunck JL; Topham CA; Ortega-Loayza AG; Kent G; Cassidy PB; Hu R; Choate K; Wang Z; Liu Y; Greiling TM
    JAMA Dermatol; 2020 Jun; 156(6):668-675. PubMed ID: 32293641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of pityriasis rubra pilaris with tildrakizumab.
    Zagarella SS; Jiang KW
    Australas J Dermatol; 2022 Feb; 63(1):120-121. PubMed ID: 34854479
    [No Abstract]   [Full Text] [Related]  

  • 5. Case of pityriasis rubra pilaris progressed to generalized erythroderma following blockade of interleukin-17A, but improved after blockade of interleukin-12/23 p40.
    Matsuda T; Yamazaki F; Ueda-Hayakawa I; Kambe N; Okamoto H
    J Dermatol; 2019 Jan; 46(1):70-72. PubMed ID: 30506728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refractory Type I pityriasis rubra pilaris treated with tildrakizumab.
    Licata G; Gambardella A; Calabrese G; Pagliuca F; Alfano R; Argenziano G
    Clin Exp Dermatol; 2021 Dec; 46(8):1594-1595. PubMed ID: 34101231
    [No Abstract]   [Full Text] [Related]  

  • 7. Pityriasis rubra pilaris: treatment with biologics - a new promising therapy?
    Ivanova K; Itin P; Haeusermann P
    Dermatology; 2012; 224(2):120-5. PubMed ID: 22508269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pityriasis rubra pilaris : Successful treatment with ixekizumab].
    Kohn D; Wetzig T
    Hautarzt; 2020 Aug; 71(8):624-626. PubMed ID: 32185430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab for the treatment of pityriasis rubra pilaris: a case report.
    Wassef C; Lombardi A; Rao BK
    Cutis; 2012 Nov; 90(5):244-7. PubMed ID: 23270195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid response of pityriasis rubra pilaris with psoriasis overlap to secukinumab.
    Cole D; Mohammad T; Lim H
    Br J Dermatol; 2019 Dec; 181(6):1331-1332. PubMed ID: 31260082
    [No Abstract]   [Full Text] [Related]  

  • 11. Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis.
    Boudreaux BW; Pincelli TP; Bhullar PK; Patel MH; Brumfiel CM; Li X; Heckman MG; Pittelkow MR; Mangold AR; Sluzevich JC
    Br J Dermatol; 2022 Nov; 187(5):650-658. PubMed ID: 35701384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of pityriasis rubra pilaris with adalimumab - case report.
    Bravo EA; Carrion L; Paucar SM; Mendoza R; Rivera C
    Dermatol Online J; 2014 Apr; 20(4):22374. PubMed ID: 24746310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical improvement of pityriasis rubra pilaris with efalizumab in a pediatric patient.
    Gómez M; Ruelas ME; Welsh O; Arcaute HD; Ocampo-Candiani J
    J Drugs Dermatol; 2007 Mar; 6(3):337-9. PubMed ID: 17373198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type III juvenile pityriasis rubra pilaris: a successful treatment with infliximab.
    Ruzzetti M; Saraceno R; Carboni I; Papoutsaki M; Chimenti S
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):117-8. PubMed ID: 18181990
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful treatment of Pityriasis rubra pilaris with brodalumab.
    De Rosa A; Gambardella A; Licata G; Alfano R; Argenziano G
    Australas J Dermatol; 2020 May; 61(2):e249-e251. PubMed ID: 31851372
    [No Abstract]   [Full Text] [Related]  

  • 16. Successful treatment of severe pityriasis rubra pilaris with secukinumab in a 3-year-old boy.
    Xu YH; Dong DD; Lin YF; Wang Q; Huang LM; Shi JQ
    Clin Exp Dermatol; 2022 Nov; 47(11):2043-2045. PubMed ID: 35906074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of treatment-resistant pityriasis rubra pilaris responsive to secukinumab.
    Simpson K; Dolianitis C
    Australas J Dermatol; 2021 Aug; 62(3):441-442. PubMed ID: 34028789
    [No Abstract]   [Full Text] [Related]  

  • 18. Pityriasis rubra pilaris with polyarthritis treated with adalimumab.
    Chiu HY; Tsai TF
    J Am Acad Dermatol; 2013 Jan; 68(1):187-8. PubMed ID: 23244382
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical response to ustekinumab in familial pityriasis rubra pilaris caused by a novel mutation in CARD14.
    Eytan O; Sarig O; Sprecher E; van Steensel MA
    Br J Dermatol; 2014 Aug; 171(2):420-2. PubMed ID: 24641799
    [No Abstract]   [Full Text] [Related]  

  • 20. Successful treatment of TNFα inhibitor-resistant pityriasis rubra pilaris with ixekizumab and acitretin.
    Chastagner M; Hoelt P; Kanitakis J; Jullien D; Villani AP
    Eur J Dermatol; 2019 Apr; 29(2):218-220. PubMed ID: 30827945
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.